Home > Oncology > ESMO 2022 > Triple therapy improves PFS in aRCC versus dual therapy

Triple therapy improves PFS in aRCC versus dual therapy

Presented By
Dr Toni Choueiri, Dana-Farber Cancer Institute, MA, USA
ESMO 2022
Phase 3, COSMIC-313
First result of the phase 3 COSMIC-313 trial demonstrate that triple therapy (cabozantinib/ nivolumab/ipilimumab) improves progression-free survival (PFS) versus dual checkpoint inhibition (nivolumab/ipilimumab) in patients with previously untreated advanced renal cell carcinoma (aRCC). Dual immune checkpoint inhibition with nivolumab plus ipilimumab is a first-line standard-of-care for patients with aRCC of IMDC intermediate or poor risk [1]. However, approximately 20% of patients experience progressive disease as best response, representing an unmet medical need. In addition, first-line cabozantinib plus nivolumab has demonstrated clinical effectiveness in patients with aRCC [2]. In a phase 1 trial, triplet therapy (nivolumab/ipilimumab/cabozantinib) showed clinical activity and manageable toxicity [3]. Based on this background, the phase 3 COSMIC-313 trial (NCT03937...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on